Tharimmune, Inc. Files Q1 2025 10-Q

Ticker: CNTN · Form: 10-Q · Filed: May 12, 2025 · CIK: 1861657

Tharimmune, INC. 10-Q Filing Summary
FieldDetail
CompanyTharimmune, INC. (CNTN)
Form Type10-Q
Filed DateMay 12, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, pharmaceutical, filing

TL;DR

Tharimmune (formerly Hillstream BioPharma) filed its Q1 2025 10-Q. No major financial updates here, just the standard filing.

AI Summary

Tharimmune, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Hillstream BioPharma Inc., is in the pharmaceutical preparations industry. Key financial data points from previous periods are referenced, but specific financial results for the current quarter are not detailed in this header information.

Why It Matters

This filing provides an update on Tharimmune's financial status and operations for the first quarter of 2025, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Tharimmune faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this header.

Key Numbers

Key Players & Entities

FAQ

What is Tharimmune, Inc.'s primary industry?

Tharimmune, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.

When is the reporting period for this 10-Q filing?

The conformed period of report is March 31, 2025.

What was Tharimmune, Inc. formerly known as?

Tharimmune, Inc. was formerly known as Hillstream BioPharma Inc. and prior to that, also Tharimmune, Inc. after a name change on September 25, 2023.

What is the company's business address?

The business address is 1200 Route 22 East, Bridgewater, NJ 08807.

What is the SEC file number for Tharimmune, Inc.?

The SEC file number is 001-41210.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Tharimmune, Inc. (CNTN).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing